346 related articles for article (PubMed ID: 34408400)
1. Establishment of Prognostic Nomograms for Predicting the Survival of HR-Positive, HER2-Negative Metastatic Breast Cancer Patients Treated with Everolimus.
Duan F; Song C; Ma Y; Jiang K; Xu F; Bi X; Huang J; Hong R; Huang Z; Lu Q; Yuan Z; Wang S; Xia W
Drug Des Devel Ther; 2021; 15():3463-3473. PubMed ID: 34408400
[TBL] [Abstract][Full Text] [Related]
2. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
3. Prognostic nomogram for patients with non-metastatic HER2 positive breast cancer in a prospective cohort.
Luo C; Zhong X; Wang Z; Wang Y; Wang Y; He P; Peng Q; Zheng H
Int J Biol Markers; 2019 Mar; 34(1):41-46. PubMed ID: 30852974
[TBL] [Abstract][Full Text] [Related]
4. A Prognostic Model Based on PAM50 and Clinical Variables (PAM50MET) for Metastatic Hormone Receptor-positive HER2-negative Breast Cancer.
Prat A; Tsai YH; Pascual T; Paré L; Adamo B; Vidal M; Brasó-Maristany F; Galván P; Brase JC; Rodrik-Outmezguine V; Johnston S; Ciruelos E; Parker JS
Clin Cancer Res; 2020 Dec; 26(23):6141-6148. PubMed ID: 32962980
[TBL] [Abstract][Full Text] [Related]
5. Establishment of prognostic nomograms for predicting the progression free survival of EGFR-sensitizing mutation, advanced lung cancer patients treated with EGFR-TKIs.
Du X; Bai H; Wang Z; Daun J; Liu Z; Xu J; Chang G; Zhu Y; Wang J
Thorac Cancer; 2022 May; 13(9):1289-1298. PubMed ID: 35347870
[TBL] [Abstract][Full Text] [Related]
6. Prognostic nomogram for patients with Nasopharyngeal Carcinoma incorporating hematological biomarkers and clinical characteristics.
Li J; Chen S; Peng S; Liu Y; Xing S; He X; Chen H
Int J Biol Sci; 2018; 14(5):549-556. PubMed ID: 29805306
[TBL] [Abstract][Full Text] [Related]
7. Preoperative Breast Immune Prognostic Index as Prognostic Factor Predicts the Clinical Outcomes of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Chen L; Kong X; Huang S; Su Z; Zhu M; Fang Y; Zhang L; Li X; Wang J
Front Immunol; 2022; 13():831848. PubMed ID: 35320931
[TBL] [Abstract][Full Text] [Related]
8. [A prognostic nomogram for metastasized colorectal cancer patients treated with cetuximab].
Zhong LP; Li D; Zhu LZ; Fang XF; Xiao Q; Ding KF; Yuan Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Jul; 23(7):701-708. PubMed ID: 32683833
[No Abstract] [Full Text] [Related]
9. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
10. Development and validation of a nomogram for predicting survival of advanced breast cancer patients in China.
Lin S; Mo H; Li Y; Guan X; Chen Y; Wang Z; Yuan P; Wang J; Luo Y; Fan Y; Cai R; Li Q; Chen S; Zhang P; Li Q; Ma F; Xu B
Breast; 2020 Oct; 53():172-180. PubMed ID: 32836201
[TBL] [Abstract][Full Text] [Related]
11. A nomogram for predicting survival in patients with de novo metastatic breast cancer: a population-based study.
Zhao W; Wu L; Zhao A; Zhang M; Tian Q; Shen Y; Wang F; Wang B; Wang L; Chen L; Zhao X; Dong D; Zhang L; Yang J
BMC Cancer; 2020 Oct; 20(1):982. PubMed ID: 33046035
[TBL] [Abstract][Full Text] [Related]
12. Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy.
Rozenblit M; Mun S; Soulos P; Adelson K; Pusztai L; Mougalian S
Breast Cancer Res; 2021 Jan; 23(1):14. PubMed ID: 33514405
[TBL] [Abstract][Full Text] [Related]
13. A Novel Nomogram for Survival Prediction of Patients with Spinal Metastasis From Prostate Cancer.
Liu Y; Li L; Jiang D; Yang M; Gao X; Lv K; Xu W; Wei H; Wan W; Xiao J
Spine (Phila Pa 1976); 2021 Mar; 46(6):E364-E373. PubMed ID: 33620180
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.
Xie J; Hao Y; Li N; Lin PL; Ohashi E; Koo V; Signorovitch JE; Wu EQ; Yardley DA
Curr Med Res Opin; 2015 Jun; 31(6):1095-103. PubMed ID: 25971725
[TBL] [Abstract][Full Text] [Related]
15. Development and validation of a prognostic nomogram for early HER2-positive and lymph node-negative breast cancer.
Shi Q; Wang J; Ai X; Xuhong J; Ma D; Zhang Y; Qi X; Jiang J
Gland Surg; 2021 Jul; 10(7):2255-2265. PubMed ID: 34422596
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of patients with HER2-positive breast cancer and development of a nomogram for predicting survival.
Fan Y; Wang Y; He L; Imani S; Wen Q
ESMO Open; 2021 Aug; 6(4):100232. PubMed ID: 34392135
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.
Yam C; Esteva FJ; Patel MM; Raghavendra AS; Ueno NT; Moulder SL; Hess KR; Shroff GS; Hodge S; Koenig KH; Chavez Mac Gregor M; Griner RL; Yeung SJ; Hortobagyi GN; Valero V
Invest New Drugs; 2019 Apr; 37(2):345-351. PubMed ID: 30610588
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Open Label Study of Everolimus in Combination With Endocrine Therapy in Resistant Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer.
Yardley DA; Liggett W; Mainwaring M; Castrellon A; Blakely L; Hemphill B; Anz B; Young RR; Shastry M; DeBusk LM; Hainsworth JD; Burris HA
Clin Breast Cancer; 2020 Apr; 20(2):89-97. PubMed ID: 31932237
[TBL] [Abstract][Full Text] [Related]
19. Development and validation of a nomogram for predicting survival of breast cancer patients with ipsilateral supraclavicular lymph node metastasis.
Lyu MH; Ma YZ; Tian PQ; Guo HH; Wang C; Liu ZZ; Chen XC
Chin Med J (Engl); 2021 Nov; 134(22):2692-2699. PubMed ID: 34743149
[TBL] [Abstract][Full Text] [Related]
20. Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study.
Jeong JH; Kim JE; Ahn JH; Jung KH; Koh SJ; Cheon J; Sohn J; Kim GM; Lee KS; Sim SH; Park IH; Kim SB
Eur J Cancer; 2021 Feb; 144():341-350. PubMed ID: 33388491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
